HC Wainwright Has Bearish Estimate for CRDL FY2026 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Cardiol Therapeutics in a research note issued to investors on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.25) for the year, down from their previous estimate of ($0.24). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2028 earnings at $0.26 EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $1.18 EPS.

Other equities analysts have also recently issued reports about the company. B. Riley Financial assumed coverage on Cardiol Therapeutics in a research report on Wednesday, August 26th. They issued a “buy” rating and a $11.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Monday, September 21st. Wall Street Zen cut Cardiol Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 14th. Finally, Canaccord Genuity Group raised their target price on Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cardiol Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Check Out Our Latest Analysis on CRDL

Cardiol Therapeutics Stock Performance

NASDAQ:CRDL opened at $0.95 on Tuesday. Cardiol Therapeutics has a 1 year low of $0.88 and a 1 year high of $2.34. The stock’s fifty day moving average price is $1.34 and its two-hundred day moving average price is $1.30.

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).

Hedge Funds Weigh In On Cardiol Therapeutics

Several hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC bought a new stake in Cardiol Therapeutics during the 3rd quarter worth approximately $32,000. Royal Bank of Canada boosted its holdings in Cardiol Therapeutics by 62.3% in the 1st quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock valued at $29,000 after purchasing an additional 8,306 shares during the period. Virtu Financial LLC bought a new position in Cardiol Therapeutics in the 3rd quarter valued at $42,000. Concurrent Investment Advisors LLC purchased a new position in shares of Cardiol Therapeutics during the 2nd quarter valued at $27,000. Finally, Cibc World Market Inc. purchased a new position in shares of Cardiol Therapeutics during the 3rd quarter valued at $55,000. Hedge funds and other institutional investors own 12.49% of the company’s stock.

About Cardiol Therapeutics

(Get Free Report)

Cardiol Therapeutics is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart. The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure.

Featured Articles

Earnings History and Estimates for Cardiol Therapeutics (NASDAQ:CRDL)

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.